Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 9, 2026, 12:54 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 73–96 of 522 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Viread Clear all

Conditions: HIV Prevention
Interventions: WePrEP: A shared decision-making tool, Active comparator: CDC recommendations for discussing PrEP; Behavioral
Lead sponsor: University of Colorado, Denver; Other
Eligibility: 18 Years to 65 Years · Male only
Enrollment: 75 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 1
States / cities: Sheridan, Colorado

Conditions: HIV Infection
Interventions: DOR/ISL, BIC/FTC/TAF, Placebo to BIC/FTC/TAF, Placebo to FDC DOR/ISL; Drug
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 18 Years and older
Enrollment: 643 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2025
U.S. locations: 28
States / cities: Phoenix, Arizona • Beverly Hills, California • Los Angeles, California + 24 more

Conditions: Human Immunodeficiency Virus
Interventions: bictegravir/emtricitabine/tenofovir alafenamide; Drug
Lead sponsor: Midland Research Group, Inc.; Other
Eligibility: 18 Years and older
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2019
U.S. locations: 1
States / cities: Oakland Park, Florida

Conditions: HIV Infections
Interventions: Etravirine (Intelence), Truvada; Drug
Lead sponsor: University of North Carolina, Chapel Hill; Other
Eligibility: 18 Years and older
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2014
U.S. locations: 3
States / cities: Chapel Hill, North Carolina • Charlotte, North Carolina • Winston-Salem, North Carolina

Conditions: HIV/AIDS
Interventions: Genvoya; Drug
Lead sponsor: Emory University; Other
Eligibility: 18 Years to 49 Years · Male only
Enrollment: 41 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019
U.S. locations: 1
States / cities: Atlanta, Georgia

Conditions: Healthy Volunteer, HIV Prevention
Interventions: tenofovir alafenamide [TAF] 50 mg/emtricitabine [FTC] 400mg; Drug
Lead sponsor: Johns Hopkins University; Other
Eligibility: 18 Years and older
Enrollment: 24 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Human Immunodeficiency Virus
Interventions: tenofovir/emtricitabine/efavirenz (TDF/FTC/EFV), tenofovir/emtricitabine (TDF/FTC), Atazanavir (ATV), Ritonavir, Phlebotomy; Drug · Procedure
Lead sponsor: University of North Carolina, Chapel Hill; Other
Eligibility: 18 Years and older
Enrollment: 85 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2014
U.S. locations: 1
States / cities: Chapel Hill, North Carolina

Conditions: Pharmacokinetic Study in Healthy Volunteers
Interventions: tenofovir + emtricitabine; Drug
Lead sponsor: University of North Carolina, Chapel Hill; Other
Eligibility: 18 Years to 49 Years
Enrollment: 12 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008 – 2009
U.S. locations: 1
States / cities: Chapel Hill, North Carolina

Conditions: Infection, Human Immunodeficiency Virus I
Interventions: Dolutegravir, Atripla, Abacavir/Lamivudine, Abacavir/Lamivudine Placebo, Dolutegravir placebo, Atripla placebo; Drug
Lead sponsor: ViiV Healthcare; Industry
Eligibility: 18 Years and older
Enrollment: 844 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2015
U.S. locations: 55
States / cities: Hobson City, Alabama • Little Rock, Arkansas • Bakersfield, California + 42 more

Conditions: HIV
Interventions: Oral FTC/TDF (Daily Emtricitabine/Tenofovir Disoproxil fumarate Tablet), Rectal Daily TFV RG 1% gel (Rectally applied Tenofovir Reduced Glycerin 1% Gel), Rectal RAI-associated TFV RG 1% gel (Receptive Anal Intercourse Associated rectally applied Tenofovir Reduced Glycerin 1% Gel); Drug
Lead sponsor: CONRAD; Other
Eligibility: 18 Years and older · Male only
Enrollment: 195 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2015
U.S. locations: 3
States / cities: San Francisco, California • Boston, Massachusetts • Pittsburgh, Pennsylvania

Conditions: HIV/AIDS
Interventions: bictegravir/emtricitabine/tenofovir alafenamide; Drug
Lead sponsor: Thomas Jefferson University; Other
Eligibility: 18 Years and older
Enrollment: 411 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2020
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: HIV Prevention
Interventions: Tenofovir enema, Saline enema; Drug · Other
Lead sponsor: Johns Hopkins University; Other
Eligibility: 18 Years and older · Male only
Enrollment: 21 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2019
U.S. locations: 3
States / cities: Los Angeles, California • Baltimore, Maryland • Pittsburgh, Pennsylvania

Conditions: HIV I Infection, Cardiovascular Risk Factor, Lipid Metabolism Disorders
Interventions: Doravirine 100 Mg; Drug
Lead sponsor: University of Texas Southwestern Medical Center; Other
Eligibility: 18 Years to 70 Years · Male only
Enrollment: 26 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2025
U.S. locations: 2
States / cities: Dallas, Texas

Conditions: HIV-1-infection
Interventions: B/F/TAF; Drug
Lead sponsor: Tulika Singh, MD; Other
Eligibility: 65 Years and older
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 1
States / cities: Palm Springs, California

Conditions: Acquired Immunodeficiency Syndrome, HIV Infections
Interventions: D/C/F/TAF, DRV, COBI, FTC/TDF, D/C/F/TAF Placebo, DRV Placebo, COBI Placebo, FTC/TDF Placebo; Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 18 Years and older
Enrollment: 153 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2014
U.S. locations: 43
States / cities: Birmingham, Alabama • Beverly Hills, California • Los Angeles, California + 31 more

Conditions: HIV-1 Infection
Interventions: FTC/RPV/TDF, PI, RTV, NRTIs; Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 18 Years and older
Enrollment: 482 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2014
U.S. locations: 66
States / cities: Birmingham, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 45 more

Conditions: Hepatitis B Virus Infection
Interventions: Flavonoid, Tenofovir; Drug
Lead sponsor: Trieu, Nguyen Thi, M.D.; Individual
Eligibility: 18 Years to 80 Years
Enrollment: 134 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2026
U.S. locations: 1
States / cities: Wilmington, Delaware

Conditions: Acquired Immune Deficiency Syndrome
Interventions: Lopinavir 400 mg/ritonavir 100 mg, Efavirenz; Drug
Lead sponsor: Rush University Medical Center; Other
Eligibility: 18 Years to 60 Years
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2011
U.S. locations: 4
States / cities: Chicago, Illinois

Conditions: HIV Infections
Interventions: Truvada, Atazanavir, Ritonavir; Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 18 Years and older
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2007
U.S. locations: 1
States / cities: Foster City, California

Conditions: HIV
Interventions: Truvada, Raltegravir; Drug
Lead sponsor: The University of Texas Health Science Center, Houston; Other
Eligibility: 18 Years and older
Enrollment: 103 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2015
U.S. locations: 1
States / cities: Houston, Texas

Conditions: HIV
Interventions: Stribild, Atripla; Drug
Lead sponsor: University of Hawaii; Other
Eligibility: 18 Years to 65 Years
Enrollment: 30 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2016
U.S. locations: 1
States / cities: Honolulu, Hawaii

Conditions: HIV-1 Infection
Interventions: Islatravir, Placebo to Islatravir, Doravirine, Placebo to Doravirine, Lamivudine, Placebo to Lamivudine, Doravirine/Lamivudine/Tenofovir Disoproxil Fumarate, Placebo to Doravirine/Lamivudine/Tenofovir Disoproxil Fumarate, Doravirine/Islatravir; Drug
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 18 Years and older
Enrollment: 123 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2022
U.S. locations: 10
States / cities: Phoenix, Arizona • Sacramento, California • Washington D.C., District of Columbia + 7 more

Conditions: HIV Infections
Interventions: Enfuvirtide, Efavirenz, lamivudine, and tenofovir; Drug
Lead sponsor: University of Maryland, Baltimore; Other
Eligibility: 18 Years to 70 Years
Enrollment: 2 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2007
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: HIV Infection, Adherence, Medication, Adherence, Treatment, Pre-Exposure Prophylaxis, Antiretroviral Therapy
Interventions: Next-generation Reader and ID-Cap System, Truvada for pre-exposure prophylaxis (PrEP), Biktarvy for antiretroviral therapy (ART); Device · Drug
Lead sponsor: Brigham and Women's Hospital; Other
Eligibility: 18 Years and older
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2024
U.S. locations: 1
States / cities: Boston, Massachusetts

Search by objective public record fields.

WePrEP: Developing a PrEP Shared Decision-making Tool for Transgender Women

Switch to Doravirine/Islatravir (DOR/ISL) in Human Immunodeficiency Virus 1 (HIV-1) Participants Treated With Bictegravir/Emtricitabine/Tenofovir Alafenamide (BIC/FTC/TAF) (MK-8591A-018)

Efficacy, Safety & Tolerability of Switching EFV/TDF/FTC to BIC/FTC/TAF in Virologically Suppressed Adults With HIV-1

Evaluating Once Daily Etravirine in Treatment-Naive Adults With HIV Infection

Body Compartment Pharmacokinetics of Anti-retroviral Agents That May be Considered for Future On-demand Peri-exposure HIV Prophylaxis Regimens

Evaluation of Single Dosing With Two F/TAF Tablets Among Healthy Volunteers

Tenofovir, Emtricitabine, Efavirenz and Atazanavir Pharmacokinetics in the Aging HIV-Infected Population

Single Dose Truvada in HIV-negative Men and Women

A Trial Comparing GSK1349572 50mg Plus Abacavir/Lamivudine Once Daily to Atripla (Also Called The SINGLE Trial)

Safety and Acceptability Study of Oral Emtricitabine/Tenofovir Disoproxil Fumarate Tablet and Rectally-Applied Tenofovir Reduced-Glycerin 1% Gel

The Incidence and Severity of Drug Interactions Before and After Switching Antiretroviral Therapy to Bictegravir/Emtricitabine/Tenofovir Alafenamide in Treatment Experienced Patients

Optimization of a Tenofovir Enema for HIV Prevention

Doravirine Versus Integrase Inhibitors on Backbone of Emtricitabine and Tenofovir Alafenamide in HIV

Study to Assess Switching to B/F/TAF in Treatment Experienced People With HIV Who Are at Least 65 Years of Age

D/C/F/TAF Versus COBI-boosted DRV Plus FTC/TDF in HIV-1 Infected, Antiretroviral Treatment Naive Adults

Study to Evaluate Switching From Regimens Consisting of a Ritonavir-boosted Protease Inhibitor (PI) and Two Nucleoside Reverse Transcriptase Inhibitors (NRTIs) to a Fixed-dose Tablet Containing Emtricitabine/Rilpivirine/Tenofovir DF

Inhibition of HBV Replication and Biological Reversal of Cirrhosis (F3-F4) and HCC by Flavonoids

Immune Reconstitution of Lopinavir/Ritonavir-Based vs Efavirenz-based HAART in Advanced HIV Disease

Boosted Atazanavir and Truvada Given Once-Daily - BATON Study

Truvada Plus Raltegravir for Nonoccupational Post-exposure Prophylaxis (nPEP)

Sleep and Cognition After Atripla to Stribild Switch

Islatravir (MK-8591) With Doravirine and Lamivudine in Participants Infected With Human Immunodeficiency Virus Type 1 (MK-8591-011)

A Study to Evaluate of the Efficacy of Enfuvirtide During the Induction Phase of Therapy

Next Generation Ingestible Sensors for Medication Adherence Measurement